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A
 
BSTRACT
 
Mast cells express high-affinity IgE receptors (Fc
 
ε
 
RI) on
their surface and can be activated to secrete a variety
of biologically active mediators by cross-linking of
receptor-bound IgE. Recent studies in animal models
indicate that mouse mast cells may play a protective
role in host defense against bacteria through the pro-
duction of tumor necrosis factor-
 
α
 
, mainly as a result
of Toll-like receptor (TLR) 4- or CD48-mediated activa-
tion. Moreover, several recent observations in animal
models have indicated that mast cells may also play a
pivotal role in coordinating the early phases of
autoimmune diseases, particularly those involving
auto-antibodies. We recently identified functional TLR4
and Fc
 
γ
 
RI on human mast cells, in which their expres-
sion had been upregulated by interferon-
 
γ
 
. We com-
pared each of the receptor-mediated gene expression
profiles with the Fc
 
ε
 
RI-mediated gene expression
profile using high-density oligonucleotide probe
arrays and discovered that human mast cells may
modulate the immune system in a receptor-specific
manner.
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I
 
NTRODUCTION
 
Mast cells are major effector cells in allergic inflamma-
tion and are located at the host–environment interface,
where they encounter not only antigens, but also invad-
ing pathogens. Recent studies in animal models indicate
that mouse mast cells may also play a protective role in
host defense against bacteria through the production of
tumor necrosis factor (TNF)-
 
α
 
, mainly as a result of Toll-
like receptor (TLR)4- or CD48 (a mannose-containing
GPI-anchored molecule)-mediated activation.
 
1,2
 
 Tissue
mast cells contain TNF-
 
α
 
 in their granules and release it
by triggered exocytosis.
 
3–5
 
 The rapid release of TNF-
 
α
 
is of note because of the pleiotropic pro-inflammatory
effects of this cytokine and because its release is more
rapid than by other cell systems,
 
6,7
 
 which require induc-
tion of synthesis after cell activation. The rapid release of
TNF-
 
α
 
 by mast cells may be important not only for
innate immunity, but also for the initiation of adaptive
immunity in infection and autoimmune diseases.
 
8–10
 
 The
present review describes the function of mast cells in
infection and autoimmune diseases in animal models,
as well as discussing the roles of Fc
 
γ
 
RI and TLR4
expressed on human mast cells.
 
M
 
AST
 
 
 
CELLS
 
 
 
IN
 
 
 
ALLERGIC
 
 
 
INFLAMMATION
 
Fc
 
ε
 
RI is expressed with 
 
α
 
-, 
 
β
 
-, and 
 
γ
 
-chains on mast
cells. It binds monomeric IgE with a K
 
a
 
 of 10
 
–10
 
 mol/L
and is believed to essentially be responsible for allergen-
dependent allergic responses.
 
11
 
 Immediate hyper-
sensitivity is an immune reaction that is initiated by
antigen binding to IgE preattached to mast cells that leads
to the secretion of inflammatory mediators. Following
aggregation of Fc
 
ε
 
RI, mast cells release biogenic
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amines, such as histamine and proteases, including
tryptase and chymase. Activated mast cells also synthe-
size prostaglandin D
 
2
 
 and leukotriene C
 
4
 
, as well as
other mediators known to cause bronchoconstriction,
mucus secretion and edema formation.
 
11
 
 The role of
mast cells in potentiating the late allergic response has
been attributed, in part, to mast cell-dependent secretion
of pro-inflammatory cytokines and chemokines
 
11
 
 and
the inflammatory infiltrates of the late phase reaction are
rich in eosinophils, basophils and Th2 cells (Fig. 1a).
 
M
 
AST
 
 
 
CELLS
 
 
 
IN
 
 
 
INNATE
 
 
 
IMMUNITY
 
Mast cells are inflammatory cells typically found in
relatively large numbers in the mucosa of the respiratory,
gastrointestinal and urinary tracts, as well as near blood
and lymphatic vessels. Because these sites are also
common portals of infection, mast cells are likely to be
one of the first inflammatory cells to come into contact
with invading pathogens and, after activation, they
release a myriad of pro-inflammatory cytokines, pro-
teases and inflammatory mediators.
 
10
 
In addition to these inflammatory mediators, mast cells
have been reported to contain antimicrobial peptides.
Peptide antibiotics have been isolated from all types of
organisms, from plants to mammals, and a novel family
of peptide antibiotics called ‘piscidins’ has recently been
isolated from fish.
 
12,13
 
 Piscidins have potent, broad-
spectrum 
 
in vitro
 
 activity against many pathogens, includ-
ing multidrug-resistant bacteria.
 
12,13
 
 Interestingly, piscidins
reside in mast cells, which are also known as eosinophilic
granule cells and are morphologically and functionally
similar to their mammalian counterparts. However,
whether these fish mast cells are derived from the same
lineage as mammalian mast cells is unclear.
 
13
 
 Cultured
murine mast cells contain cathelicidins and their expres-
sion is inducible by lipopolysaccharide (LPS) or lipo-
teichoic acid.
 
14
 
 Human skin mast cells have also been
reported to express cathelicidins (LL-37) as a result of
their detection by immunohistochemical analysis.
 
14
 
 Thus,
mast cells may participate directly in killing microbes.
A number of studies have confirmed that mast cells
play a critical role in host immune defense against
Gram-negative bacteria through the release of TNF-
 
α
 
.
As shown in two different models of acute bacterial
infection, mast cell-deficient W/W
 
v
 
 mice are less efficient
in clearing the pathogenic bacteria in cecal ligation
and  puncture (CLP)-induced peritonitis or from the
lungs  of mice challenged intranasally with 
 
Klebsiella
pneumoniae
 
.
 
15,16
 
 CD48 has been demonstrated to be
the mast cell membrane receptor for 
 
Escherichia coli
 
expressing the fimbrial adhesion molecule FimH.
 
17
 
 The
interaction between CD48 and bacterial FimH results
in mast cell degranulation and concomitant bacterial
uptake via lipid rafts.
 
17
 
Murine mast cells have been reported to express TLR2
and TLR4.
 
2,18
 
 Peptidoglycan (PGN) from 
 
Staphylococcus
aureus
 
 stimulates murine bone marrow-derived mast
cells (mBMMC) to produce TNF-
 
α
 
, interleukin (IL)-4, IL-5,
IL-6 and IL-13 in a TLR2-dependent manner, but not
IL-1
 
β
 
,
 
2
 
 and TLR2-dependent mast cell stimulation results
in mast cell degranulation and Ca
 
2+
 
 mobilization.
 
2
 
 The
mBMMC and the murine mast cell line MC/9 express
TLR4 mRNA
 
2,18,19
 
 and, when activated with 
 
E. coli
 
-derived
LPS, murine mast cells produce TNF-
 
α
 
, IL-1
 
β
 
, IL-6 and
IL-13, but not IL-4 or IL-5.
 
2,18
 
 A study using a mast
cell-dependent model of acute sepsis revealed higher
mortality by TLR4-mutated mBMMC-reconstituted W/W
 
v
 
mice and that TLR4 deficiency in bone marrow mast cells
in mice results in significantly higher mortality because of
defective neutrophil recruitment and production of pro-
inflammatory cytokines in the peritoneal cavity.
 
2
 
 These
findings in murine models suggest that mast cells play
important roles in the expression of innate immunity
through TLR4.
In humans, cord blood-derived mast cells express
mRNA for TLR1, TLR2 and TLR6, but not TLR4.
 
20
 
 Bacterial
peptidoglycan and yeast zymosan, the putative TLR2/
TLR6 activators, are potent inducers of granulocyte–
macrophage colony stimulating factor (GM-CSF) and
IL-1
 
β
 
 and also induce substantial short-term cysteinyl
leukotriene generation.
 
20
 
 In contrast, a synthetic tri-
acylated lipopeptide, the putative TLR2/TLR1 activator,
induces short-term degranulation but does not induce
cysteinyl leukotriene production.
 
20
 
 Varadaradjalou
 
et al.
 
21
 
 have reported that both LPS from 
 
E. coli
 
 and PGN
induce significant release by cord blood-derived mast
cells of not only TNF-
 
α
 
, but also histamine, IL-5, IL-10
and IL-13. Stimulation with PGN induces histamine
release.
We investigated the expression of TLR4 on human
adult peripheral blood-derived cultured mast cells and
discovered functional expression of TLR4 that is upregu-
lated following IFN-
 
γ
 
 exposure.
 
22
 
 To explore system-
atically how human mast cells modulate the immune
system in response to pathogen and antigen, we com-
pared the LPS-induced gene expression profiles in mast
cells with the Fc
 
ε
 
RI-mediated profiles using high-density
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oligonucleotide probe arrays (GeneChip; Affimetrix,
Santa Clara, CA, USA). The results showed both a shared
core response and LPS- or antigen-specific programs of
gene expression in the mast cells. Mast cells also exhib-
ited an antiviral-response gene program in response to
IFN-
 
γ
 
 and LPS sustained the expression of the antiviral
response-gene program (Fig. 1b). When compared with
the LPS-stimulated gene expression profile in peripheral
blood mononuclear cells, the LPS-stimulated mast cells
specifically induce a Th2 cytokine and chemokines
against Th2 cells and eosinophils. These results reveal
that human mast cells elicit tailored pathogen- and
 
Fig. 1
 
(a)
 
 
 
Fc
 
ε
 
RI-mediated mast cell activation. Mast cells express high-affinity IgE receptors (Fc
 
ε
 
RI) on their surface and can be
activated to secrete a variety of biologically active mediators, such as histamine, lipid mediators and cytokines, by cross-linking of
receptor-bound IgE. These mediators cause bronchoconstriction, mucous secretion and edema formation,
 
11
 
 as well as activation
of inflammatory cells, such as eosinophils and Th2 cells. (b)
 
 
 
Toll-like receptor (TLR) 4-mediated mast cell activation. The TLR4 on
human mast cells is upregulated by interferon (IFN)-
 
γ
 
.
 
22
 
 Lipopolysaccharide (LPS) activates mast cells through TLR4 and induces the
expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-
 
α
 
, interleukin (IL)-1
 
β and IL-6, and the cytokines, in
turn, activate macrophages and recruit neurophils. Mast cells also express an antiviral-response gene program in response to IFN-
γ and LPS sustained this expression. (c) FcγRI-mediated human mast cell activation. Human mast cells express the high-affinity IgG
receptor FcγRI on their surface and the expression of FcγRI is upregulated by IFN-γ. Aggregation of FcγRI on human mast cells results
in histamine release, the generation of prostaglandin D2 and leukotriene C4 and the production of a variety of cytokines. Pro-
infammatory cytokines, such as TNF-α and IL-1β, in particular, were found to be upregulated in mast cells following the aggregation
of FcγRI compared with aggregation of FcεRI.52
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antigen-specific immune responses and that human mast
cells may have an important role in innate immunity as
well as adaptive immunity.
MAST CELLS IN AUTOIMMUNE DISEASES
Numerous studies have reported a correlation between
the number and/or distribution of mast cells and the
development of autoimmune diseases, such as multiple
sclerosis and rheumatoid arthritis. As an example, evi-
dence for mast cell activation in the course of multiple
sclerosis came from an immunohistochemical demon-
stration of increasing degranulation in the brain in an
animal model23 and increased amounts of tryptase in
the cerebrospinal fluid.24 Gene expression profiling of
multiple sclerosis brain lesions detected a high contribu-
tion of transcripts, such as proteases and other inflam-
matory mediators, derived from mast cells.25,26 It is also
well known that mast cells accumulate in the synovial
tissues and fluids of humans with rheumatoid arthritis.27
Experimental allergic encephalomyelitis (EAE) is an
experimental model of multiple sclerosis, a chronic
inflammatory disorder of the central nervous system that
is characterized by a breach of the blood–brain barrier,
mononuclear cell infiltration of white matter and even-
tual demyelinization. Secor et al.28 showed that mice
lacking mast cells (W/Wv mice) develop EAE later and
less severely than control wild-type mice in response to
injection of different myelin components, such as myelin
oligodendrocyte glycoprotein. Complementation of
W/Wv mice with immature mast cells derived in vitro
restored typical EAE susceptibility. Mast cell function
appears to be dependent on the expression of FcγR, in
particular FcγRIII, by mast cells.28 This is true in animal
models of rheumatoid arthritis29 and bullous pem-
phigoid.30 Immune complexes may aggregate FcγR to
release TNF-α, which recruits neutrophils.8,9
EXPRESSION OF THE LOW-AFFINITY IGG 
RECEPTORS FCγRII AND FCγRIII ON MURINE 
MAST CELLS
There have been extensive studies on the expression of
FcγRII and FcγRIII on murine mast cells. Interleukin-3-
dependent mBMMC express the low-affinity IgG recep-
tors FcγRIIb1 and FcγRIIb2, and mouse serosal mast
cells also express FcγRIII.31,32 Mature serosal mast cells
degranulate when exposed to IgG complexes,33 whereas
mBMMC appear to internalize aggregated IgG without
release of substantial amounts of histamine.32 In later
studies, it was reported that FcγRIIb inhibits FcεRI-
mediated degranulation of mBMMC and rat basophilic
leukemia cells34,35 because of the ability of FcγRIIb
to recruit Src homology 2 domain-bearing inositol
5-phoshatase.36 Mouse mast cells alter the surface
expression of certain IgG receptors.37 The mBMMC
upregulate the surface expression of FcγRIII when cul-
tured with 3T3 fibroblasts,37 which may be functionally
important because cocultured mBMMC degranulate and
generate various lipid mediators when their FcγRIII
receptors are cross-linked.33 Mast cells have also been
shown to play a role in immune complex-induced injury
related to the expression of IgG receptors in a mouse
model.38–40 As mentioned above, several recent obser-
vations indicate that mast cells may also have a key role
in coordinating the early phase of autoimmune diseases,
particularly those involving auto-antibodies.28–30 How-
ever, the roles of FcγR in human mast cells in auto-
immune diseases remain to be determined.
HUMAN FCγ RI FAMILY GENE PRODUCTS AND 
STRUCTURE
Three FcγRI genes (i.e. Fcγ RIA, Fcγ RIB and Fcγ RIC) have
been identified as encoding at least six transcripts:
FcγRIa1, FcγRIa2, FcγRIb1, FcγRIb2, FcγRIb3 and
RcγRIc.41,42 The Fcγ RIA gene product FcγRIA1 uniquely
contains a third extracellular domain (EC3), as well as
transmembrane and cytoplasmic domains.41,42 The pres-
ence of these domains, together with the presence of
EC2, allows this gene product to bind monomeric IgG
with high affinity and to initiate IgG-mediated cellular
responses.43 Two transcripts (b1 and c) have stop
codons in EC3 and are believed to only code for soluble
secreted proteins.41 Three transcripts are alternatively
spliced isoforms, one (a2) from gene A and two (b2 and
b3) from gene B.42 FcγRIb2 lacks EC341 and is not
expressed on the cell surface.44 FcγRIb3 lacks the signal
sequences (S) 2, EC1 and EC3.42 FcγRIa2 lacks the S2
and EC1.42 The protein product and function of FcγRIa2
and FcγRIb3 are unknown.42 Thus, FcγRIa1 is the only
full-length gene product and binds IgG with high affinity
(Ka 10–8 to 10–9 mol/L). It is expressed at the cell surface
as an αγ2 complex.45 The full-length FcγRI presents three
extracellular Ig-like domains on the extracellular portion
of its α chain. FcRγ chains are required for surface
expression of FcγRI on monocytes, macrophages,
neutrophils, dendritic cells and eosinophils46 and for
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signaling mediated by FcγRI.41 FcγRI expression has
been shown to be influenced by immune cytokines. For
example, monocytes, macrophages and neutrophils
constitutively express FcγRI, but surface expression of
FcγRI on neutrophils is strongly increased by IFN-γ.47
EXPRESSION OF A FUNCTIONAL HIGH-AFFINITY 
IGG RECEPTOR (FCγRI) ON HUMAN MAST 
CELLS
Because of the increasing body of evidence in animal
models that mast cells may be recruited into allergic
reactions by non-IgE-dependent mechanisms and the
fact that FcγRIII has been shown to induce murine mast
cell degranulation, we hypothesized that human mast
cells may also express Fcγ receptors and that the
expression of these receptors may be affected by specific
factors produced in the microenvironment. Human mast
cells derived from CD34+ progenitors in peripheral
blood were obtained by culture of progenitor cells with
recombinant human (rh) IL-3, rhIL-6 and stem cell factor
(SCF) and then for 6–8 weeks with rhIL-6 and SCF.48
These culture conditions yielded a cell population that
was 97% human mast cells, as assessed by Toluidine
blue staining, and the mast cell cultures were then
enriched to greater than 99.9% mast cells by removing
monocytes by adherence. We first determined using
reverse transcription–polymerase chain reaction (RT-PCR)
that resting human mast cells contain mRNA for Fcγ RIa1,
Fcγ RIb2, Fcγ RIIA, Fcγ RIIb1, Fcγ RIIb2 and Fcγ RIII,49,50 and
then investigated whether pro-inflammatory cytokines
can influence the expression of Fcγ receptors on human
mast cells. Mast cells were incubated with IL-4, IL-5,
IL-10, GM-CSF, nerve growth factor or IFN-γ, but only
IFN-γ upregulated the expression of Fcγ RIa1 and
Fcγ RIb2.49 As described above, FcγRIb2 appears not to
be present on the surface membrane, not to bind
to either monomeric or complexed IgG and not to be
recognized by antibodies to the high-affinity IgG recep-
tor.44 Thus, according to the results of RT-PCR, human
mast cells express the high-affinity IgG receptor, the
gene product of Fcγ RIA, and Fcγ RI mRNA expression
was maximal between 4 and 8 h, when the increase was
approximately 10-fold of the baseline level. This was
confirmed by flow cytometry, which showed that IFN-γ
exposure increased FcγRI expression on human mast
cells from approximately 2 to 44%. The intensity of
surface expression of FcγRI was maximal at 24 h and
appeared to plateau from 24 h through to 48 h. The
expression of FcεRI, FcγRII and FcγRIII was unaffected.
The expression of FcγRII and FcγRIII in human mast cells
was approximately 45 and 0.5%, respectively.49
Although murine mast cells express a functional FcγRIII,
FcγRIII protein expression was minimal and unaltered by
permeabilization.50 The presence of FcγRI on the mast
cell surface was further confirmed by immunoprecipita-
tion. The human mast cell FcγRI had a molecular mass
of approximately 72 kDa,49 the same as FcγRI expressed
by human monocytes.51 Scatchard plots of FcγRI using
[125I]-labeled human IgG1 were consistent with these
data and the average number of binding sites for
monomeric IgG1 (Ka = 4–5 × 10–8 mol/L) increased
from approximately 2400 to 12 000–17 300 per cell.49
Thus, human mast cells express the high-affinity IgG
receptor FcγRI and a low-affinity IgG receptor (FcγRII)
on their surface and the expression of FcγRI is upregu-
lated by IFN-γ. Aggregation of FcγRI on human mast
cells resulted in histamine release, the generation of
prostaglandin D2 and leukotriene C4 and the production
of a variety of cytokines. Pro-infammatory cytokines,
such as TNF-α and IL-1β, were particularly upregulated
in mast cells following the aggregation of FcγRI com-
pared with the aggregation of FcεRI52 (Fig. 1c). Because
both the FcεRI α chain and the FcγRI α chain require
FcRγ (common γ chains) for signal transduction,53 the
FcεRI- and FcγRI-induced gene expression profile
appeared to be similar. However, we did find some
differences (Y Okayama et al., unpubl. data, 2004),
and we are now confirming the data at the protein level.
CONCLUSIONS
We recently identified a subset of genes that is specifi-
cally induced by stimulation through TLR4 and not
stimulated by aggregation of FcεRI. Interferon-γ induced
a variety of receptors, such as FcγRI, in mast cells and
antiviral-response genes were also induced. In addition,
we identified a subset of genes that is specifically
induced in FcγRI-mediated mast cells. Thus, human mast
cells exhibit tailored pathogen- and antigen-specific
immune responses, suggesting that human mast cells
may play important roles in innate and adaptive
immunity.
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